Cytogen, Inc. Stock

A217330

KR7217330000

Biotechnology & Medical Research

End-of-day quote Korea S.E. 2026-09-11			5-day change	1st Jan Change
3,055.00 ^KRW	-1.13%		+1.33%	-66.02%

05-17	Cytogen, Inc. announced that it expects to receive KRW 5.2 billion in funding from BNK Securities Co.,Ltd., Hanyang Securities Co. Ltd. and other investors.	CI
11-05	Cytogen wins 1 billion won order	RE

Cytogen Inc is a Korea-based company mainly engaged in the provision of liquid biopsy application services. The liquid biopsy application services include biomarker discovery and verification services, as well as liquid biopsy-based precision medical services which is the commercialization of companion diagnostics (CDx) development, among others. The biomarker discovery and verification services include circulating tumor cell (CTC)-based biomarker discovery and validation, gene mutation and transcript expression analysis, and drug testing and analysis services, among others. The liquid biopsy-based precision healthcare services include companion diagnosis, re-selection of therapeutic drugs, examination and treatment effectiveness monitoring, and recurrence prediction services, among others. In addition, the Company develops and sells platforms and kits for liquid biopsy. The Company distributes its products within the domestic market and to overseas markets.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-09-11	₩3,055.00	-1.13%	62,146
26-09-10	₩3,090.00	+1.31%	47,200
26-09-09	₩3,050.00	-0.49%	45,336
26-09-08	₩3,065.00	+0.33%	45,834
26-09-07	₩3,055.00	+1.33%	70,791

End-of-day quote Korea S.E.

More quotes

Stock Market
Stocks
A217330 Stock

40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!

SEIZE THE OFFER!

Market Cap	70.65B 52.71M 45.41M 43M 38.98M 73.12M 5.04B 73.49M 511M 196M 2.56B 198M 194M 8.1B	P/E 2024	-5.98x	P/E 2025	-16.8x
Enterprise Value	55.42B 41.34M 35.62M 33.73M 30.57M 57.36M 3.95B 57.65M 401M 154M 2.01B 155M 152M 6.35B	EV / Sales 2024	7.17x	EV / Sales 2025	7.38x
Free-Float	58.21%	Yield 2024 *	-	Yield 2025	-

05-17	Cytogen, Inc. announced that it expects to receive KRW 5.2 billion in funding from BNK Securities Co.,Ltd., Hanyang Securities Co. Ltd. and other investors.	CI
11-05	Cytogen wins 1 billion won order	RE
25-09-10	Cytogen sells 160 million won worth of own shares	RE
25-01-02	Cytogen Moves to Dual CEO Arrangement	MT
24-09-22	Cytogen, Inc.(KOSDAQ:A217330) dropped from S&P Global BMI Index	CI
24-08-21	Cytogen, Inc. announced that it has received KRW 6.500000445 billion in funding from Theragen Etex Co.,Ltd.	CI
24-07-30	Cytogen, Inc. agreed to acquire 98.95% stake in Theragen Genomecare Co. Ltd from Theragen Etex Co.,Ltd. and Daeilgen Bio for KRW 13.2 billion.	CI
24-03-19	Cytogen, Inc. announced that it has received KRW 9.8 billion in funding from NH Investment & Securities Co., Ltd., Samsung Securities Co., Ltd. and other investors	CI
24-03-17	Cytogen, Inc. announced that it expects to receive KRW 9.8 billion in funding from NH Investment & Securities Co., Ltd., Samsung Securities Co., Ltd. and other investors	CI
23-12-27	Cytogen, Inc. announced that it has received KRW 55.49999 billion in funding from CanDx Holdings Limited	CI
23-12-27	Cytogen, Inc. announced that it expects to receive KRW 99.999821616 billion in funding from Candx Holdings Limited	CI
23-12-18	Candx Holdings Limited agreed to acquire a 31.96% stake in Cytogen, Inc. from Jeon Byung Hee and others for KRW 110 billion	CI
23-10-26	Cytogen, Inc. announces tranche update	CI

1 day	-1.13%
1 week	+1.33%
Current month	-2.86%
1 month	-16.87%
3 months	-24.00%
6 months	-34.30%
Current year	-66.02%

1 week	2,995	3,105
1 month	2,965	3,715
Current year	2,760	11,200
1 year	2,260	11,200
3 years	2,260	17,500
5 years	2,260	23,066.67
10 years	2,260	24,166.67

Manager	Title	Age	Since
Ji-Hun Ahn CEO	Chief Executive Officer	45	2025-01-01
Byeong-Hui Jeon CEO	Chief Executive Officer	67	2025-01-01
Young-Woong Son PRN	Corporate Officer/Principal	52	2025-03-30

Cytogen, Inc. Stock

Stocks

A217330

KR7217330000

Biotechnology & Medical Research

Valuation : Cytogen, Inc.

Chart: Cytogen, Inc.

Latest news : Cytogen, Inc.

Quotes and Performance

Price Extremes

Managers and Directors : Cytogen, Inc.

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Director	Title	Age	Since
Byeong-Hui Jeon BRD	Director/Board Member	67	2025-01-01
Ji-Hun Ahn BRD	Director/Board Member	45	2025-01-01
Seung-Gi Min BRD	Director/Board Member	64	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CYTOGEN, INC.	-1.13%	+1.33%	+14.42%	-81.51%	52.71M
LONZA GROUP AG	-0.71%	-6.35%	-4.87%	+9.03%	45.48B
REVOLUTION MEDICINES, INC.	+0.21%	-2.98%	+340.68%	+519.93%	43.69B
IQVIA HOLDINGS INC.	+1.74%	-2.24%	+37.28%	+21.57%	43.09B
BEONE MEDICINES AG	+1.38%	-3.28%	+3.23%	+65.60%	39.4B
CELLTRION, INC.	-1.44%	-5.26%	+8.78%	+36.85%	31.91B
ASCENDIS PHARMA A/S	+0.87%	-2.60%	-	-	17.31B
MEDPACE HOLDINGS, INC.	+0.75%	-0.64%	+18.07%	+110.32%	16.4B
EUROFINS SCIENTIFIC SE	-0.31%	-2.78%	+10.47%	+30.49%	14.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+1.93%	-3.55%	+74.20%	+39.37%	13.28B
Average	+0.33%	-3.22%	+55.81%	+83.52%	26.48B
Weighted average by Cap.	+0.41%	-3.67%	+73.15%	+123.52%

	2024	2025
Net sales	10.91B 8.14M 7.01M 6.64M 6.02M 11.29M 778M 11.35M 78.87M 30.33M 396M 30.57M 29.9M 1.25B	26.05B 19.44M 16.75M 15.86M 14.37M 26.96M 1.86B 27.1M 188M 72.42M 945M 73M 71.4M 2.99B
Net income	-17.12B -12.77M -11M -10.42M -9.44M -17.71M -1.22B -17.8M -124M -47.58M -621M -47.96M -46.91M -1.96B	-12.34B -9.21M -7.93M -7.51M -6.81M -12.77M -880M -12.84M -89.22M -34.31M -448M -34.58M -33.82M -1.41B
Net Debt	-26.39B -19.69M -16.97M -16.06M -14.56M -27.32M -1.88B -27.46M -191M -73.37M -957M -73.95M -72.33M -3.02B	-15.23B -11.36M -9.79M -9.27M -8.4M -15.77M -1.09B -15.85M -110M -42.34M -552M -42.68M -41.74M -1.75B